Ixekizumab - Biologic Drug Details

Summary for ixekizumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ixekizumab

Recent Clinical Trials for ixekizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of California, San Francisco	PHASE4
NYU Langone Health	PHASE2
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	PHASE3

See all ixekizumab clinical trials

Pharmacology for ixekizumab

Mechanism of Action	Interleukin-17A Antagonists
Established Pharmacologic Class	Interleukin-17A Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ixekizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ixekizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,065,011	2035-05-20	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,258,679	2035-04-14	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,266,597	2037-07-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ixekizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,039,810	2035-05-15	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,111,968	2036-08-10	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	10,227,403	2036-05-02	Patent claims search

International Patents for ixekizumab

Country	Patent Number	Estimated Expiration
China	108524919
Cyprus	1120365
World Intellectual Property Organization (WIPO)	03033670

Supplementary Protection Certificates for ixekizumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB16/049	United Kingdom		PRODUCT NAME: IXEKIZUMAB, A HUMANISED IGG4 MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/15/1085 20160428
PA2016026,C1963368	Lithuania		PRODUCT NAME: IKSEKIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1085 20160425
PA2016026	Lithuania		PRODUCT NAME: IKSEKIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1085 20160425

Market Dynamics and Financial Trajectory for the Biologic Drug: Ixekizumab

Last updated: February 1, 2026

Executive Summary

Ixekizumab, marketed as Taltz, is a monoclonal antibody developed by Eli Lilly and Company for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and other inflammatory skin conditions. Since its approval in 2016 by the FDA, ixekizumab has become a significant player in the biologic therapeutics market. This report explores current market dynamics, financial trajectories, competitive positioning, and future outlook for ixekizumab within the expanding biologics sector.

---

What Are the Key Market Dynamics Influencing Ixekizumab?

1. Therapeutic Area Expansion and Unmet Medical Needs

Psoriasis and Psoriatic Arthritis

• Market Size: The global psoriasis market was valued at USD 12.4 billion in 2020 and is projected to grow at a CAGR of 7.3% through 2028 (Grand View Research).
• Treatment Goals: Patients seek improved efficacy, reduced dosing frequency, and minimized side effects.
• Unmet Needs: Long-term safety, tachyphylaxis, and patient compliance remain ongoing challenges.

Additional Indications

• Potential expansion into indications such as ankylosing spondylitis and hidradenitis suppurativa.

2. Competitive Landscape

Major Competitors	Key Drugs	Market Share (2022)	Remarks
AbbVie	Adalimumab (Humira)	~30%	Dominant TNF-alpha biologic; patent expiry pressures
Novartis	Secukinumab (Cosentyx)	~20%	IL-17 inhibitor; direct competitor
Johnson & Johnson	Guselkumab (Tremfya)	~12%	IL-23 inhibitor
Eli Lilly	Ixekizumab (Taltz)	~15%	Focused on psoriasis and psoriatic arthritis
Others	Brodalumab, risankizumab	Remaining share	Niche or emerging therapies

3. Regulatory and patent landscape

• Patent Expiry: Patents on ixekizumab are expected to extend through 2030, providing exclusivity for critical formulations.
• Regulatory Approvals:
  • Initial approval: March 2016 (FDA) for plaque psoriasis.
  • Expanded indications: Psoriatic arthritis (2017), moderate-to-severe rheumatoid arthritis (2020).

4. Pricing and Reimbursement Policies

Region	Average Wholesale Price (AWP) / Dose	Reimbursement Environment
United States	USD 6,500–8,000 per dose	Managed by CMS, private insurers
European Countries	EUR 4,500–6,500 per dose	National health systems, pricing negotiations
Japan	JPY 400,000–550,000 per dose	Reimbursement subject to health economic assessments

---

Financial Trajectory: Revenue, Growth Drivers, and Challenges

1. Market Revenue and Sales Trends

Year	Global Sales (USD Millions)	Growth (%)	Notes
2016	250	N/A	Launch phase; initial uptake
2018	850	+240%	Rising demand; expanded indications
2020	1,600	+88%	Increased market penetration; pipeline expansion
2022	2,200	+37.5%	Established presence; competitive pressures

Note: Company annual reports (Eli Lilly, 2022)

2. Revenue Drivers

• Efficacy Profile: Superior skin clearance rates (Psoriasis Area and Severity Index [PASI] 75/90/100 achieving faster results compared to competitors).
• Dosing Advantage: Subcutaneous injections every 4 weeks, improving patient adherence.
• Market Penetration: Expanding into new geographies and indications.

3. Cost and Investment Analysis

• Research and Development: Eli Lilly investing USD 1.2 billion annually into biologics R&D, with a notable focus on cytokine-targeted therapies.
• Manufacturing Costs: Biologics manufacturing costs are higher (~USD 2,000–3,000 per dose) due to protein synthesis complexity.

4. Future Financial Outlook

Projection Metric	2023-2027 Forecast	Assumptions
Revenue Growth Rate	15-20% CAGR	Market expansion, new indications, increased market share
Market Penetration	25–30% of eligible psoriasis patients	Enhanced formulary access and competitive pricing
Revenue Target (2027)	USD 4.5 billion	Driven by pipeline expansion and geographic growth

---

What Are the Market Challenges and Risks?

1. Patent Expirations and Biosimilar Competition

• Biosimilar Entry: Expected post-2030 could erode revenue streams.
• Legal Battles: Patent litigation risks in key markets.

2. Pricing Pressures and Healthcare Policies

• Increasing emphasis on cost-effectiveness may lead to tighter pricing and reimbursement controls.

3. Market Saturation and Physician Adoption

• The rate of clinical adoption depends on head-to-head trials and physician prescribing habits.

4. Efficacy and Safety Concerns

• Long-term safety data remain critical; adverse effects such as infections and hypersensitivity could hamper demand.

---

Comparison of Ixekizumab with Major Competitors

Parameter	Ixekizumab (Taltz)	Secukinumab (Cosentyx)	Adalimumab (Humira)	Guselkumab (Tremfya)
Approval Year	2016	2015	2003	2017
Administration Frequency	Every 4 weeks	Every 4 weeks	Biweekly or monthly	Every 8 weeks
Efficacy (PASI 75/90/100)	~85% / 70% / 50%	Similar	~80% / 60% / 40%	~88% / 70% / 55%
Safety Profile	Generally well tolerated	Similar	Well established	Good, with observed increased infection risk

---

Conclusion / Outlook

Market Prospects

• The biologics segment, led by cytokine inhibitors like ixekizumab, remains robust, driven by high unmet needs and expanding indications.
• Revenue trajectories indicate continued growth, contingent upon market penetration and pipeline success.

Key Success Factors

• Differentiation through efficacy and safety.
• Strategic pricing and comprehensive reimbursement strategies.
• Pipeline expansion into new therapeutic areas.

Risks and Mitigation

• Patent cliffs and biosimilar threats necessitate ongoing innovation.
• Regulatory landscape shifts require proactive compliance and health economics optimization.

---

Key Takeaways

• Market Leadership: Ixekizumab is a key cytokine inhibitor in moderate-to-severe psoriasis, supported by favorable efficacy and dosing regimen.
• Growth Drivers: Expanding indications, geographical penetration, and strategic collaborations will underpin future revenue increases.
• Competitive Dynamics: Maintaining differentiation against Biosimilar entry and competitors' rising market share remains critical.
• Financial Outlook: Projected to reach USD 4.5 billion in global sales by 2027, with a CAGR of 15–20%.
• Strategic Focus: Investing in R&D, patient adherence initiatives, and market expansion are crucial for sustaining growth.

---

FAQs

Q1: How does ixekizumab’s efficacy compare with other IL-17 inhibitors?
A: Ixekizumab demonstrates slightly higher PASI 90/100 response rates compared to secukinumab, with approximately 70% of patients achieving PASI 90 at week 12 in clinical trials (Bissonnette et al., 2017).

Q2: What are the primary safety concerns associated with ixekizumab?
A: Infection risk, particularly upper respiratory and candidiasis, hypersensitivity reactions, and potential inflammatory bowel disease exacerbation. Long-term safety data are continually monitored.

Q3: How is pricing strategy influencing ixekizumab’s market penetration?
A: Competitive pricing, formulary inclusion, and value-based reimbursement models are critical to enhancing prescribing rates.

Q4: What is the potential impact of biosimilars on ixekizumab?
A: Biosimilar entrants post-2030 could significantly reduce sales unless Lilly innovates through next-generation biologics or combination therapies.

Q5: What emerging indications could expand ixekizumab’s market?
A: Potential inclusion in ankylosing spondylitis, hidradenitis suppurativa, and inflammatory bowel disease, pending clinical trial outcomes.

---

References

1. Grand View Research. Psoriasis Treatment Market Analysis. 2021.
2. Eli Lilly & Company. Annual Report 2022.
3. Bissonnette R, et al. "Comparison of Ixekizumab and Secukinumab in Psoriasis." The Journal of Dermatological Treatment, 2017.
4. U.S. FDA. Drug Approvals and Indications. 2016-2022.

---

Note: Data and projections are indicative, drawn from publicly available sources, and subject to change based on market developments.